Base to Base biotech podcast 70: Taking the lead on GI motility disorders

This week, we have a conversation with Peter G. Milner, founder and director of Renexxion, about GI motility disorders.RenexxionRenexxion, Inc. is a privately held US-headquartered clinical-stage biopharmaceutical company, with a subsidiary in Ireland, committed to developing new therapies for patients with gastrointestinal disorders.Renexxion’s lead program is naronapride, a late-stage drug candidate being developed for multiple unmet indications in the upper and lower GI tract.Dr. Falk Pharma GmbH, a research-based pharmaceutical company specializing in digestive and metabolic medicine, and Renexxion recently announced positive results from MOVE-IT, a global phase 2b, randomised placebo-controlled trial evaluating the efficacy, safety, and tolerability of naronapride in adults with gastroparesis.To get in touch with guest suggestions, or to sponsor or advertise on the podcast, please email [email protected]